𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma

✍ Scribed by Massimo Imbriaco; Samuel D. J. Yeh; Henry Yeung; JiaJu Zhang; John H. Healey; Paul Meyers; Andrew G. Huvos; Steven M. Larson

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
166 KB
Volume
80
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

The maximum pixel counts taken over the tumor divided by those taken of a background region yielded a tumor-to-background ratio. The percentage of change 1 Nuclear Medicine Service, Memorial Sloanin the tumor-to-background ratio before and after chemotherapy, defined as the Kettering Cancer Center, New York, New York.

alteration ratio, was correlated with the percentage of tumor necrosis. The percent-2 Orthopaedic Service, Memorial Sloan-Ketterages of tumor necrosis were classified into 4 grades: Grade 1, õ50%; Grade 2, 50-

📜 SIMILAR VOLUMES

Imaging assessment of the responses of o
Imaging assessment of the responses of osteosarcoma patients to preoperative chemotherapy : Angiography compared with thallium-201 scintigraphy
✍ Toshiyuki Kunisada; Toshifumi Ozaki; Akira Kawai; Shinsuke Sugihara; Kohji Taguc 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 2 views

## BACKGROUND. Assessment of the responses of osteosarcoma patients to preoperative chemotherapy is of clinical importance. The purpose of this study was to estimate the accuracy of angiography and thallium-201 scintigraphy, compared with histology, in assessing the responses of patients with oste

B cell depletion may be more effective t
B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents
✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt